Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease
Authors not listed
University of Wisconsin, Madison · 2001
Abstract
The aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Anonymous. (2001). Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease. <em>University of Wisconsin, Madison</em>. https://clinicaltrials.gov/study/NCT00065767
Vancouver
Anonymous. Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease. University of Wisconsin, Madison. 2001.
BibTeX
@misc{anon2001Cognit,
title = {Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease},
author = {Anonymous},
journal = {University of Wisconsin, Madison},
year = {2001},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Ageing Research Reviews 2020
Preprint · OA
Defective mitophagy in Alzheimer’s disease
The Lancet 2021
Preprint · OA
Alzheimer's disease
Handbook of clinical neurology 2019
Citation only
Alzheimer's disease
Eli Lilly and Company 2014
Open access · US-GOV
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Nature Reviews Neurology 2024
Preprint · OA
Is Alzheimer disease a disease?
US Department of Veterans Affairs 1999
Open access · US-GOV